QuartataWeb
Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics
 

Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: target; # of requested predictions: 20; Secondary interactions: no
Input target 1: P11362
No. Gene UniProt ID Protein Name Pathway PDB
1 FGFR1 P11362 Fibroblast growth factor receptor 1 hsa04010; hsa04014; hsa04015; hsa04151; hsa04520; hsa04550; hsa04714; hsa04810; hsa04928; hsa05200; hsa05205; hsa05215; hsa05218; hsa05224; hsa05230


13 known interactions (drugs) of input target (FGFR1): Fibroblast growth factor receptor 1
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image
1 Experimental SmallMoleculeDrug DB07840 (E)-[4-(3,5-difluorophenyl)-3H-pyrrolo[2,3-b]pyridin-3-ylidene](3-methoxyphenyl)methanol Thumb
2 Approved;
Investigational		 SmallMoleculeDrug DB12010 Fostamatinib Thumb
3 Approved;
Investigational		 SmallMoleculeDrug DB01109 Heparin Thumb
4 Approved BiotechDrug DB00039 Palifermin Thumb
5 Approved SmallMoleculeDrug DB08896 Regorafenib Thumb
6 Experimental SmallMoleculeDrug DB07525 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine Thumb
7 Experimental SmallMoleculeDrug DB02058 SU4984 Thumb
8 Approved;
Investigational		 SmallMoleculeDrug DB00398 Sorafenib Thumb
9 Approved SmallMoleculeDrug DB09079 Nintedanib Thumb
10 Approved;
Investigational		 SmallMoleculeDrug DB08901 Ponatinib Thumb
11 Experimental SmallMoleculeDrug DB08577 3-[(3-(2-CARBOXYETHYL)-4-METHYLPYRROL-2-YL)METHYLENE]-2-INDOLINONE Thumb
12 Approved;
Investigational		 SmallMoleculeDrug DB09078 Lenvatinib Thumb
13 Investigational SmallMoleculeDrug DB05014 XL999 Thumb


20 predicted interactions (drugs) of input target (FGFR1): Fibroblast growth factor receptor 1
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter		 Image Confidence score
1 Approved;
Investigational		 SmallMoleculeDrug DB01254 Dasatinib Thumb 59.0%
2 Approved SmallMoleculeDrug DB06589 Pazopanib Thumb 57.7%
3 Approved;
Investigational		 SmallMoleculeDrug DB01268 Sunitinib Thumb 54.5%
4 Approved SmallMoleculeDrug DB00619 Imatinib Thumb 45.2%
5 Investigational SmallMoleculeDrug DB06080 ABT-869 Thumb 44.5%
6 Approved;
Investigational		 SmallMoleculeDrug DB06595 Midostaurin Thumb 44.2%
7 Approved BiotechDrug DB10770 Foreskin fibroblast (neonatal) Thumb 39.5%
8 Investigational SmallMoleculeDrug DB05146 XL820 Thumb 36.6%
9 Investigational SmallMoleculeDrug DB05913 OSI-930 Thumb 35.6%
10 Approved BiotechDrug DB10772 Foreskin keratinocyte (neonatal) Thumb 34.7%
11 Experimental SmallMoleculeDrug DB01901 Sucrosofate Thumb 34.6%
12 Investigational SmallMoleculeDrug DB05075 TG-100801 Thumb 34.1%
13 Investigational SmallMoleculeDrug DB12742 Amuvatinib Thumb 32.8%
14 Approved;
Investigational		 SmallMoleculeDrug DB06626 Axitinib Thumb 32.4%
15 Experimental SmallMoleculeDrug DB02491 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine Thumb 31.5%
16 Investigational SmallMoleculeDrug DB04879 Vatalanib Thumb 31.2%
17 Approved;
Investigational		 SmallMoleculeDrug DB08875 Cabozantinib Thumb 30.3%
18 Investigational BiotechDrug DB06101 IMC-1C11 Thumb 29.8%
19 Investigational SmallMoleculeDrug DB05984 RAF-265 Thumb 29.1%
20 Approved;
Investigational		 SmallMoleculeDrug DB08912 Dabrafenib Thumb 28.0%


  logl

Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.

Contact:

The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.